Remove 2026 Remove Scoliosis Remove Treatment
article thumbnail

SpineGuard and Omnia Medical Announce the Signature of a Binding Term Sheet for the Transfer of SpineGuard Inc.

OrthoSpineNews

This transaction is part of SpineGuard’s objective of reaching operational breakeven by the end of 2026. In addition, this transaction will enable us to significantly lighten our cost structure, as such it is an important catalyst for reaching our goal of operational breakeven by the end of 2026. BOULDER, Co., Ciaran Bolger, M.D.,

Spine 52
article thumbnail

SpineGuard Announces Full-Year 2024 Financial Results and First Quarter 2025 Sales

OrthoSpineNews

SpineGuard could present its advances at the end-of-year congresses of SRS (Scoliosis Research Society), NASS (North American Spine Society) and Eurospine, generating considerable interest. It could also be useful for prescribing bone-strengthening treatments post-operatively. DSG was co-invented by Maurice Bourlion, Ph.D.,

X-ray 52
article thumbnail

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3Pâ„¢ Pediatric Plating Platformâ„¢ Hip System

OrthoSpineNews

3P Pediatric Plating Platform Hip System is a new plate and screw platform to modernize and revolutionize trauma and deformity correction treatment in the lower extremities. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. This represents the companys 5 th FDA approval in 2025.